scholarly journals Expression of multidrug resistance membrane transporter (Pgp) and p53 protein in canine mammary tumours

2014 ◽  
Vol 62 (2) ◽  
pp. 194-204 ◽  
Author(s):  
Zsófia Koltai ◽  
Péter Vajdovich
Keyword(s):  
Multidrug Resistance ◽  
P53 Protein ◽  
Malignant Tumours ◽  
P Glycoprotein ◽  
Mammary Tumours ◽  
Tumour Suppressor Protein ◽  
Expression Rate ◽  
Highly Correlated ◽  
Benign Tumours ◽  
Mouse Antibody

The aim of this study was to determine the expression rate of P-glycoprotein (Pgp), a multidrug resistance marker and the p53 tumour-suppressor protein in canine mammary tumours. A total of 30 tumours were examined in parallel to patient history. The tumours were allotted to four groups: tubulopapillar carcinomas, complex carcinomas, benign tumours, and other malignant tumours. A monoclonal mouse antibody (C494) was used for the immunohistochemical evaluation of Pgp and a polyclonal rabbit antibody for p53. We found that the intact ductal epithelium and connective tissue showed pronounced Pgp expression. The most intensive staining was detected in tubulopapillar carcinomas for both Pgp and p53. The expression rate of Pgp and p53 differed significantly between tubulopapillar carcinoma and complex carcinoma, and between tubulopapillar carcinoma and benign mammary tumour, respectively. The expressions of Pgp and p53 highly correlated statistically; therefore, both can determine malignancy in a similar manner. In the case of tubulopapillar carcinomas, more relapsed tumours occurred than in relation to complex carcinomas and other malignant tumours. Pgp expression rate was proportional to the probability of the tumour becoming recidivant postoperatively, as well. These results suggest that routine evaluation of Pgp expression in canine mammary tumours may be prognostically helpful.

scholarly journals Differential stromal reprogramming in benign and malignant naturally occurring canine mammary tumours identifies disease-promoting stromal components

2019 ◽  
Author(s):  
Parisa Amini ◽  
Sina Nassiri ◽  
Alexandra Malbon ◽  
Enni Markkanen
Keyword(s):  
Screening Method ◽  
Malignant Tumours ◽  
Differential Abundance ◽  
Naturally Occurring ◽  
Mammary Tumours ◽  
Ffpe Specimen ◽  
Summary Statement ◽  
Benign Tumours ◽  
Laser Capture ◽  
Laser Capture Microdissected

AbstractThe importance of cancer-associated stroma (CAS) for initiation and progression of cancer is well accepted. However, as stromal changes in benign forms of naturally occurring tumours are poorly understood, it remains unclear how CAS from benign and malignant tumours compare. Spontaneous canine mammary tumours are viewed as excellent models of human mammary carcinomas (mCA). We have recently reported highly conserved stromal reprogramming between canine and human mCA based on transcriptome analysis of laser-capture-microdissected FFPE specimen. To identify stromal changes between benign and malignant mammary tumours, we have analysed CAS and matched normal stroma from 13 canine mammary adenomas and compared them to 15 canine mCA. Our analyses revealed distinct stromal reprogramming even in small benign tumours. While similarities in stromal reprogramming exist, the CAS signature clearly distinguished adenomas from mCA, suggesting that it may reliably discriminate between benign and malignant tumours. We identified strongly discriminatory genes and found strong differential enrichment in several hallmark signalling pathways between benign and malignant CAS. The distinction between CAS from adenoma and mCA was further substantiated by differential abundance in cellular composition. Finally, to determine key players in CAS reprograming between adenomas and mCA, a network-based gene screening method identified modules of co-expressing genes with distinct expression profile in benign and malignant CAS, and revealed several hub genes as potential molecular drivers in CAS. Given the relevance of canine CAS as a model for the human disease, our approach identifies potential stromal drivers of tumour malignancy with implications for human mCA.Summary statementRNAsequencing-based analysis of stromal reprogramming between benign and malignant naturally occurring canine mammary tumours identifies potential molecular drivers in cancer-associated stroma that support tumour growth and malignancy.

scholarly journals Immunohistochemical study of IGF-I and IGF-II expression in canine mammary tumours: Prognostic and diagnostic role

2020 ◽  
Author(s):  
Ozlem Ozmen
Keyword(s):  
Normal Breast ◽  
Human Breast ◽  
Malignant Tumours ◽  
Immunohistochemical Expression ◽  
Mammary Tumours ◽  
Igf I ◽  
Diagnostic Role ◽  
Benign Tumours ◽  
Breast Tissues ◽  
Insulin Like Growth Factors

AbstractMammary tumours are among the most common tumours in dogs and are of interest due to their similarities to human breast tumours. Insulin-like growth factors (IGFs) are considered important in cell growth and development. The aim of this study was to investigate the immunohistochemical expression of IGF-I and IGF-II in benign and malignant canine mammary tumours. In this study, 10 benign and 10 malignant mammary tumours from the archives of the Department of Pathology were used, and five normal breast tissues were used as controls. It was observed that the expression of IGF-I and IGF-II was low to absent in benign tumours and increased in malignant tumours. The expression of IGF-II was higher than that of IGF-I. This study showed that IGF-I and IGF-II can be used as criteria for malignancy in canine mammary tumours. The results also indicate that IGF-I and IGF-II may be used as early diagnostic markers, and their inhibition may be used for the treatment of canine and human mammary tumours in the future.

scholarly journals Patient Survival Periods and Death Causes Following Surgical Treatment of Mammary Gland Tumours Depending on Histological Type of Tumour: Retrospective Study of 221 Cases

2010 ◽  
Vol 79 (2) ◽  
pp. 289-297 ◽  
Author(s):  
Jana Lorenzová ◽  
Michal Crha ◽  
Helga Kecová ◽  
Lucie Urbanová ◽  
Renata Stavinohová ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Surgical Treatment ◽  
Mammary Tumour ◽  
Malignant Tumours ◽  
Histological Subtypes ◽  
Tubular Carcinoma ◽  
Mammary Tumours ◽  
Tumour Group ◽  
Benign Tumours ◽  
Death Causes

This retrospective study evaluated a canine patient group operated on for mammary neoplasms (221 females). After surgical treatment, the animals were divided based on histological findings into groups and subgroups according to the WHO system. In the individual groups and subgroups the length of their survival following a mammary tumour surgery and death causes were followed. Of their total number, 164 tumours were malignant, 39 were benign and 18 were mammary hyperplasias. With regard to malignant tumours, invasive tubular carcinoma (20.81%) was identified most frequently; fibroadenoma reached the highest occurrence (10.41%) as regards benign tumours. The length of survival in females with malignant tumours ranged from 12 to 37.4 months, depending on histological subtypes. In females with benign mammary neoplasms the length of survival ranged from 39.1 to 59.3 months and in animals with hyperplasia it was 50.2 months. As a result of mammary tumour, 41 females (25%) died in the malignant tumour group, none died in the benign tumour group and 2 females (11.1%) died in the hyperplasia group. The survival periods in surgically treated patients with mammary tumours were shorter for solid and complex carcinomas, compared to patients affected with the remainder of the histological subtypes. The longest survival period following operation was recorded in the group suffering from adenoma. The least favourable illness prognosis for patients with mammary tumours in respect to linking the death cause to the mammary tumour was for those having invasive papillary carcinoma. The most favourable illness prognosis was for patients with benign tumours and non-invasive tubular carcinoma. A frequent death cause in females with mammary tumours was another illness unrelated to mammary tumours.

Transfection with Protein Kinase Cα Confers Increased Multidrug Resistance to MCF-7 Cells Expressing P-Glycoprotein

1991 ◽  
Vol 3 (6) ◽  
pp. 181-189 ◽  
Author(s):  
Gang Yu ◽  
Shakeel Ahmad ◽  
Angelo Aquino ◽  
Craig R. Fairchild ◽  
Jane B. Trepel ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Protein Kinase ◽  
P Glycoprotein ◽  
Protein Kinase Cα ◽  
Mcf 7

scholarly journals Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents

1989 ◽  
Vol 264 (30) ◽  
pp. 18031-18040
Author(s):  
L A Mickley ◽  
S E Bates ◽  
N D Richert ◽  
S Currier ◽  
S Tanaka ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Resistance Gene ◽  
Multidrug Resistance Gene ◽  
P Glycoprotein ◽  
Differentiating Agents ◽  
Mdr 1

Designing potent inhibitors against the multidrug resistance P-glycoprotein

2021 ◽  
pp. 1-13
Author(s):  
Shafi Mahmud ◽  
Md. Jahirul Islam ◽  
Md. Rimon Parves ◽  
Md. Arif Khan ◽  
Lamiya Tabussum ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
P Glycoprotein

scholarly journals Retraction Note: Flavonoids modulate multidrug resistance through wnt signaling in P-glycoprotein overexpressing cell lines

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
S. Mohana ◽  
M. Ganesan ◽  
N. Rajendra Prasad ◽  
D. Ananthakrishnan ◽  
D. Velmurugan
Keyword(s):  
Multidrug Resistance ◽  
Wnt Signaling ◽  
Cell Lines ◽  
P Glycoprotein ◽  
Overexpressing Cell

An amendment to this paper has been published and can be accessed via the original article.

scholarly journals Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein.

1991 ◽  
Vol 266 (29) ◽  
pp. 19858-19864
Author(s):  
J.P. Jaffrézou ◽  
J.M. Herbert ◽  
T. Levade ◽  
M.N. Gau ◽  
P. Chatelain ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Channel Blocker ◽  
Photoaffinity Labeling ◽  
P Glycoprotein
Sign in / Sign up

Export Citation Format

Share Document